𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Drug targeting to the liver with lactosylated albumins: Does the glycoprotein target the drug or is the drug targeting the glycoprotein?

✍ Scribed by Peter van der Sluijs; Hans P. Bootsma; Bart Postema; Frits Moolenaar; Dirk K. F. Meijer


Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
775 KB
Volume
6
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


The isolated perfused rat liver preparation was employed to study hepatic disposition of the model drugcarrier conjugate fluorescein-lactosylated albumin (F-L.HSA) with special reference to the influence of the organic anion fluorescein on liver cell specificity of the endocytomd neoglycoprotein. Hepatic clearance of fluoreseehated neoglycoproteins was significantly faster than clearance of radioiodinated neoglycoproteins. Perfusate clearance of F-L,HSA and F-LzaHSA could not completely be inhibited by a dose of 10 mg asialmrosomucoid that saturates the hepatocyte receptor-mediated endocytic process. From these data, we inferred an additional hepatic uptake mechanism, competing with the Ashwell-receptor-mediated internalization of galactoseterminated glycoproteins. Clearance experiments with fluoresceinated 'zsI-human serum albumin in the presence of the polyanionic probe dextran sulfate revealed a nearly complete (-90%) inhibition of hepatic uptake, while also a pronounced effect WM obtained with colloidal carbon. These data point to nonparenchymal cell uptake of fluoresceinated protein via interaction with scavenger receptors. In wash-out studies, it was shown that about 25% of ligand sequestrated by sinusoidal liver cells escaped degradation and recycled to the perfusion medium. Our results show that care should be taken in the use of neoglycoproteins as drug carriers to hepatocytes, since a load of only 2 to 3 moles fluorescein per mole neoglycoprotein considerably affects intrahepatic distribution. The relative contribution of nonparenchymal cell uptake by coupling of acidic drugs to the neo- glycoproteins is very probably inversely related to the number of exposing galactose groups per molecule neoglycoprotein. This phenomenon of "inversed targeting" could therapeutically both be useful or detrimental, dependent on the spectrum of cell types that should be reached by the drug.

Mammalian hepatocytes possess a receptor specific for plasma glycoproteins with terminal p-D-galactose or Nacetyl-a-D-galactosamine residues (1). Interaction with


πŸ“œ SIMILAR VOLUMES


Drug targeting to the liver with bile ac
✍ Dirk K. F. Meijer πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 457 KB

Bile acids are selectively taken up from portal blood into the liver by specific transport systems in the hepatocyte plasma membrane. Therefore, studies were performed to evaluate the potential of bile acids as shuttles to deliver drugs specifically to the liver. The alkylating cytostatic drug chlor

Anticancer drugs that target metabolism:
✍ Ioanna Papandreou; Tereza Goliasova; Nicholas C. Denko πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 500 KB

## Abstract Recent findings in the fields of oncogenic regulation of metabolism, mitochondrial function and macromolecular synthesis have brought tumor metabolism and the Warburg effect back into the scientific limelight. A number of metabolic pathways that seem to be important for tumor growth are

Chemical modification of therapeutic dru
✍ L. Juillerat-Jeanneret; F. Schmitt πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 266 KB

## Abstract Most therapeutic drugs distribute to the whole body, which results in general toxicity and poor acceptance of the treatments by patients. The targeted delivery of chemotherapeutics to defined cells, either stromal or cancer cells in cancer lesions, or defined inflammatory cells in immun